List of Excipients in Branded Drug BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	CELLULOSE, MICROCRYSTALLINE
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	CROSPOVIDONE
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	FERRIC OXIDE RED
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	HYDROGENATED CASTOR OIL

Generic Drugs Containing BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	CROSPOVIDONE
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	HYDROGENATED CASTOR OIL
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	LACTOSE MONOHYDRATE
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	POLOXAMER 188

What are the Most Frequently-Used Excipients in BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
12	CROSPOVIDONE

Excipient Strategy and Commercial Opportunities for Benazepril Hydrochloride and Hydrochlorothiazide

Last updated: February 25, 2026

What is the Current Formulation and Excipient Use?

Benazepril hydrochloride combined with hydrochlorothiazide (HCTZ) is marketed primarily as a fixed-dose combination therapy for hypertension and heart failure. The marketed formulations, such as Lotrel, typically include excipients that ensure stability, bioavailability, and patient acceptability.

Common Excipients in Existing Products:

• Binders: Cellulose derivatives (e.g., microcrystalline cellulose)
• Fillers/Diluents: Lactose monohydrate, dibasic calcium phosphate
• Disintegrants: Cross carmellose sodium
• Lubricants: Magnesium stearate
• Coatings: Hydroxypropyl methylcellulose (HPMC), povidone

The selection of excipients depends on the formulation form—tablet or capsule—and targeted release profile.

How Does Excipient Strategy Influence Formulation Development?

Excipients impact drug stability, manufacturability, bioavailability, and patient compliance. Designing an excipient strategy involves balancing these factors:

• Stability: Protects benazepril's acid-labile nature. Use milder disintegrants and protective coatings.

• Bioavailability: Ensures dissolution rate matches bioequilibrium. Use solubilizers or wet granulation techniques as needed.

• Manufacturability: Compatibility with high-speed production. Select excipients with uniform flow properties and compressibility.

• Patient Acceptability: Minimize excipients linked to adverse reactions (e.g., lactose intolerance). Consider taste-masking if chewables or suspensions are developed.

Potential for Novel Excipient Utilization

Innovative excipients could enhance product profiles:

• Cyclodextrins: Improve solubility and stability of benazepril.
• Superdisintegrants: Accelerate absorption in fixed-dose formulations.
• Biodegradable coatings: Extend shelf life and modify release profiles.
• Osmotic agents: Enable controlled release, reducing dosing frequency.

Market and Commercial Opportunities

Opportunities through Excipient Innovation:

• Extended-release formulations: Use of osmotic or matrix systems can differentiate products, allowing once-daily dosing, improving adherence.
• Reduced excipient load: Developing low-excipient formulations enhances tolerability, especially for sensitive populations.
• Flexible delivery forms: Creating dispersible tablets or multiparticulates with optimized excipient blends can target pediatric and geriatric markets.

Regulatory Considerations:

• New excipients or formulations require regulatory validation, but innovations can provide patent opportunities and market exclusivity.
• US FDA and EMA guidance emphasize safety profiles for excipients, favoring generally recognized as safe (GRAS) substances.

Competitive Landscape:

• Large pharmaceutical firms dominate the market with established formulations.
• Niche players can leverage excipient innovations for differentiated products, especially in markets with unmet needs, such as pediatric or renal impairment populations.

Supply Chain Risks:

• Dependence on specific excipients may pose risk if supply disruptions occur.
• Diversification and safety stock of key excipients are critical.

Strategic Approaches to Excipient Development

• Invest in research to identify excipients that improve stability and absorption.
• Form alliances with excipient manufacturers to access new materials.
• Develop flexible formulations adaptable to various markets and patient needs.
• Incorporate patient-centric features—taste-masking, ease of swallowing.

Investment and R&D Outlook

• The global excipient market is projected to reach $7.5 billion by 2025, growing at an annual rate of 6% (MarketsandMarkets, 2021).
• Novel excipients can command premium pricing if they deliver tangible benefits.
• Regulatory pathways favor advancements that enhance safety and efficacy, supporting innovation investments.

Summary of Key Data

Aspect	Details
Existing excipients	Microcrystalline cellulose, lactose, cross carmellose sodium, magnesium stearate
Innovation focus	Controlled-release systems, taste-masking, minimal excipient load
Market size	$7.5 billion for excipients globally (2021)
Regulatory trends	Emphasis on safety, GRAS status, validated excipient performance

Key Takeaways

• Formulation success hinges on excipient selection tailored to stability, bioavailability, and patient needs.
• Innovation opportunities include controlled-release systems and low-excipient formulations.
• Patentability and differentiation depend on novel excipient use and delivery technology.
• Regulatory environments favor safe, well-characterized excipients that enable improved therapy profiles.
• Market growth supports continued investments in excipient innovation, especially for fixed-dose combinations like benazepril/hydrochlorothiazide.

FAQs

Q1: What challenges exist in developing excipient strategies for benazepril combinations?
A1: Benazepril’s acid-labile nature demands excipients that protect stability, and fixed-dose formulations require careful compatibility with multiple active ingredients.

Q2: Can new excipients significantly improve the bioavailability of benazepril?
A2: Yes. Using solubilizers like cyclodextrins can enhance solubility, potentially translating to improved absorption.

Q3: Are there regulatory hurdles for innovative excipients?
A3: Yes. New excipients require safety validation and regulatory approval, potentially lengthening development timelines.

Q4: How do excipient choices impact patient compliance?
A4: Excipients influence taste, swallowability, and tolerability, affecting adherence, especially in pediatric and elderly populations.

Q5: What market segments are most receptive to excipient innovations in benazepril formulations?
A5: The pediatric, geriatric, and controlled-release markets show significant receptivity to formulations with optimized excipient profiles.

---

References

1. MarketsandMarkets. (2021). Excipients Market by Type, Formulation, Application, and Region. Retrieved from https://www.marketsandmarkets.com/
2. U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products.
3. European Medicines Agency. (2019). Guideline on Excipients in the Label and Package Leaflet of Medicinal Products.